NCT03211988 2026-03-02
Entinostat Neuroendocrine (NE) Tumor
Columbia University
Phase 2 Terminated
Clinical Trials
29 trialsNCT05987176 2026-01-14
NELMAS
Imperial College London
Phase 2 Terminated
NCT07012330 2025-06-10
Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients
Erasmus Medical Center
Phase 2 Terminated
NCT02489604 2025-01-13
LUNET
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Terminated
NCT02736448 2025-01-13
Lu-Ca-S
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Terminated
NCT03420521 2024-01-09
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT02859064 2023-12-05
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT03724409 2023-11-28
Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases
University of Iowa
Phase EARLY_PHASE1 Terminated
NCT03986593 2023-07-05
Cryoablation of Bone Metastases From Endocrine Tumors
Instituto do Cancer do Estado de São Paulo
Phase NA Terminated
NCT00227617 2023-05-22
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
University of California, San Francisco
Phase 2/3 Terminated
NCT04077372 2023-01-27
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers
Stanford University
Phase NA Terminated
NCT03190213 2021-06-22
Pembro NEC
University of Utah
Phase 2 Terminated
NCT03670030 2021-06-10
A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System
Ochsner Health System
Phase 2 Terminated
NCT04073017 2021-05-21
Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency
Vanderbilt-Ingram Cancer Center
Phase NA Terminated
NCT03001349 2021-02-15
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Terminated
NCT00985946 2019-12-09
Study of Panobinostat in Patients With Neuroendocrine Tumors
University of Wisconsin, Madison
Phase 2 Terminated
NCT02177773 2019-11-12
DOTA-TOC
University of California, San Francisco
Phase 1/2 Terminated
NCT04140409 2019-10-25
SCIROCCO
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 4 Terminated
NCT03014297 2019-08-08
Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression
University of Kentucky
Phase 1 Terminated
NCT00227136 2018-04-13
Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion
Western University, Canada
Phase 3 Terminated
NCT01508104 2017-08-23
Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors
University of Cincinnati
Phase 1 Terminated
NCT02359500 2017-05-03
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
Icahn School of Medicine at Mount Sinai
Phase 1 Terminated
NCT01719861 2017-04-17
Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
Stanford University
Phase 2 Terminated
NCT00947167 2017-03-03
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Stanford University
Phase 2 Terminated
NCT01163526 2017-01-30
Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
Stanford University
Terminated
NCT02078843 2016-09-07
GaIN
Insel Gruppe AG, University Hospital Bern
Phase 1/2 Terminated
NCT01755182 2016-05-06
LOTUS
National Cancer Institute, Naples
Phase 3 Terminated
NCT01215578 2015-04-30
NET
Assistance Publique - Hôpitaux de Paris
Phase 2 Terminated
NCT01886287 2015-01-12
P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated